Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
Admitted local publications that cite Abstract No: 335 Efficacy and safety of obinutuzumab β in primary membranous nephropathy: 104-week results from a phase 3, randomized, controlled trial.
